Gut Microbiome-Based Management of Patients With Heart Failure: JACC Review Topic of the Week

J Am Coll Cardiol. 2023 May 2;81(17):1729-1739. doi: 10.1016/j.jacc.2023.02.045.


Despite therapeutic advances, chronic heart failure (HF) is still associated with significant risk of morbidity and mortality. The course of disease and responses to therapies vary widely among individuals with HF, highlighting the need for precision medicine approaches. Gut microbiome stands to be an important aspect of precision medicine in HF. Exploratory clinical studies have revealed shared patterns of gut microbiome dysregulation in this disease, with mechanistic animal studies providing evidence for active involvement of the gut microbiome in development and pathophysiology of HF. Deeper insights into gut microbiome-host interactions in patients with HF promise to deliver novel disease biomarkers, preventative and therapeutic targets, and improve disease risk stratification. This knowledge may enable a paradigm shift in how we care for patients with HF, and pave the path toward improved clinical outcomes through personalized HF care.

Keywords: cardiomyopathy; gut microbiome; heart failure; personalized medicine; precision medicine.

Publication types

  • Review

MeSH terms

  • Animals
  • Gastrointestinal Microbiome* / physiology
  • Heart Failure* / therapy
  • Precision Medicine